Platelet Dysfunction in Patients With Bleeding Disorder of Unknown Cause (TARGET-BDUC)
Platelet Dysfunction in Bleeding Disorder of Unknown Cause: Novel Diagnostic and Therapeutic Targets of Platelet Dysfunction in Patients With Bleeding Disorder of Unknown Cause - The TARGET-BDUC Study
Bleeding disorder of unknown cause (BDUC) affects people who experience excessive bleeding despite normal routine laboratory tests. Undetected platelet dysfunction may contribute to their bleeding symptoms.
The TARGET-BDUC study aims to investigate platelet function, particularly the formation of procoagulant platelets, and identify underlying mechanisms and potential diagnostic biomarkers.
The study will include 100 patients with BDUC and 30 healthy controls. Advanced platelet function testing, imaging, and proteomic and lipidomic analyses will be performed.
The findings may improve the diagnosis of BDUC and help identify patients who could benefit from targeted treatment.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
This single-center observational study will recruit 100 patients with bleeding disorder of unknown cause (BDUC) from the Vienna Bleeding Biobank (VIBB) at the Medical University of Vienna and 30 age- and sex-matched healthy controls from the Vienna Bleeding Study (VIBS).
Patients with BDUC will have a clinically relevant bleeding phenotype despite normal conventional hemostatic testing, including light transmission aggregometry, and at least one prolonged PFA-100 closure time.
All participants will undergo comprehensive platelet function testing. For detailed mechanistic and multi-omics analyses, 30 BDUC patients with reduced procoagulant platelet formation, 30 BDUC patients with normal procoagulant platelet formation, and 30 healthy controls will be selected.
An exploratory substudy will assess platelet function before and after desmopressin (DDAVP) administration in 10 patients with BDUC and 5 comparison participants receiving DDAVP as part of routine clinical care.
Beskrivelse
Inclusion Criteria:
Patients with bleeding disorder of unknown cause (BDUC):
- Age ≥16 years.
- Diagnosis of BDUC following comprehensive hemostatic evaluation without identification of a specific bleeding disorder.
- Abnormal ISTH Bleeding Assessment Tool (ISTH-BAT) score (≥4 in men or ≥6 in women).
- Normal light transmission aggregometry (LTA).
- Prolonged PFA-100 closure time in at least one cartridge (collagen/epinephrine or collagen/ADP).
- Written informed consent.
Healthy controls:
- Age ≥16 years.
- No history of abnormal bleeding or thrombosis.
- Age- and sex-matched to the BDUC study population.
- Written informed consent.
Exclusion Criteria:
- Pregnancy.
- Recent surgery or infection.
- Active malignancy.
- Thrombocytopenia (platelet count <100 × 10⁹/L).
- Liver dysfunction (prothrombin time activity <75%).
- Renal impairment (eGFR <60 mL/min/1.73 m²).
- Use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or other medications affecting platelet function within 10 days before blood sampling.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Procoagulant Platelet Formation in Patients With BDUC Compared With Healthy Controls
Tidsramme: At baseline (single blood sample collected at enrollment; no follow-up assessment).
|
Procoagulant platelet formation will be quantified by flow cytometry following dual platelet stimulation with TRAP-6 and CRP-XL. Procoagulant platelets will be identified by simultaneous CD62P and lactadherin positivity, indicating platelet activation and phosphatidylserine exposure. The percentage of procoagulant platelets will be compared between patients with bleeding disorder of unknown cause (BDUC) and healthy controls to identify impaired procoagulant platelet responses. |
At baseline (single blood sample collected at enrollment; no follow-up assessment).
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- KLP1389626
- KLP1389626 (Andet bevillings-/finansieringsnummer: Austrian Science Fund (FWF))
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .